Vonjo (Pacritinib Citrate) Patent Expiration, LOE Window & CMS Spending

Vonjo (Pacritinib Citrate) by Sobi: FDA Orange Book core substance LOE 2030-03-25, 0 AB generics, $116.3M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSobi
FDA Application & PathwayN208712 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2030-03-25
Last Listed Patent or Exclusivity Date2030-03-25
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$116.3M
2024 Medicare Part D Spend$110.8M
2024 Medicaid Spend$5.5M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 32.7% 2-yr change)